Infectious Diseases
Latest news
274 articles · 20 / page
Daily Chlorhexidine Bathing in the ICU: Re-evaluating Infection Prevention and Antimicrobial Stewardship through the CLEAN-IT Trial
This review synthesizes findings from the CLEAN-IT trial and historical data to evaluate the impact of chlorhexidine bathing on nosocomial infections, MDR pathogens, and reserve antibiotic consumption in critically ill patients.
Daily Chlorhexidine Bathing in the ICU: Results from the CLEAN-IT Multicentre Trial
A large-scale trial in Brazilian ICUs found that daily chlorhexidine bathing did not lower overall nosocomial infection rates but significantly reduced multi-drug resistant pathogen isolation and the use of high-priority reserve antibiotics
Long-term Immunological and Clinical Outcomes of Monkeypox Virus Infection versus MVA-BN Vaccination: A 24-Month Longitudinal Cohort Analysis
This 24-month Belgian cohort study demonstrates that natural MPXV infection induces more durable and robust immunity than MVA-BN vaccination. While clinical symptoms mostly resolve within a year, persistent scarring remains common, and vacc
Fractional Yellow Fever Vaccination Fails Non-Inferiority in Infants: Why Adult Data Cannot Be Extrapolated to Pediatric Populations
A randomized, double-blind trial in Kenya and Uganda reveals that a 500 IU fractional dose of yellow fever vaccine is not non-inferior to the standard dose in infants, suggesting that lower dose requirements in adults are not generalizable
Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial
The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for o
Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection
This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potenti
Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial
This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.
Strategic Release of Wolbachia-Infected Mosquitoes Reduces Dengue Risk by Over 70% in Urban Singapore
A large-scale cluster-randomized trial in Singapore demonstrates that releasing male Aedes aegypti mosquitoes infected with the wAlbB Wolbachia strain significantly suppresses wild-type populations and reduces the incidence of symptomatic d
Molecular Mimicry Unveiled: How Somatic Hypermutation and Adenoviral Protein pVII Drive VITT
Researchers have identified that a specific somatic hypermutation (K31E) in the IGLV3-21*02/03 allele triggers VITT by causing antibodies intended for adenoviral protein pVII to cross-react with Platelet Factor 4 (PF4), explaining the patho
Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial
The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping cl
Beyond Symptom Resolution: Physiological Recovery Lags Behind Subjective Wellness in COVID-19 and Influenza
A 2-year prospective cohort study reveals that physiological recovery, measured via smartwatches, significantly lags behind self-reported symptom resolution, particularly in moderate-to-severe COVID-19 cases, suggesting a need for revised p
Early Inpatient Initiation of 1-Month TB Preventive Therapy Proves Non-Inferior for Patients with Advanced HIV and Cryptococcal Meningitis
The IMPROVE trial demonstrates that starting a one-month isoniazid-rifapentine (1HP) course during hospitalization for cryptococcal meningitis is as safe and effective as outpatient initiation, potentially increasing treatment completion ra
Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance
Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibito
Obesity Linked to Three-Fold Increase in Severe Infection Risk: A Global Analysis of 925 Pathogens
A large-scale multicohort study reveals that adult obesity significantly increases the risk of hospitalization and death across nearly 1,000 infectious diseases, accounting for approximately one in ten infection-related deaths globally.
Recombinant Herpes Zoster Vaccine Demonstrates Safety and Non-Inferiority in Patients with Autoimmune Rheumatic Diseases
A phase 4 RCT in Brazil confirms that the recombinant zoster vaccine does not increase the risk of disease flares in patients with autoimmune rheumatic diseases compared to placebo, maintaining a favorable safety profile even under immunosu
Fentanyl and Xylazine Dominate the Illicit Supply: New Multi-City Data Reveal Deepening Polysubstance Crisis
This toxicological analysis of out-of-treatment people who inject drugs across five major US cities found that 93% tested positive for fentanyl, while xylazine prevalence surged in the Northeast, underscoring the critical need for real-time
RSV Frequently Precedes Influenza Peaks: Mapping the Temporal Sequence of the Post-Pandemic Triple-Threat in the United States
A retrospective study of 148 state-level seasons reveals that RSV typically peaks three weeks before influenza, while COVID-19 lacks consistent seasonality, providing a critical framework for optimizing hospital resource allocation and vacc
2024-2025 COVID-19 Vaccines Provide 79% Protection Against Critical Illness Despite Viral Evolution
A multicenter study reveals that 2024-2025 COVID-19 vaccines offer 40% protection against hospitalization and 79% against critical illness or death, maintaining efficacy against emerging JN.1 descendants like KP.3.1.1 and XEC.
RSV-Related Hospitalization Linked to Surge in Acute Myocardial Infarction and Stroke Risk
A large-scale study reveals that RSV hospitalization significantly increases the risk of myocardial infarction, stroke, and heart failure exacerbations, with the highest risk occurring within the first week post-admission, emphasizing the c
Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality
The Phase IIa INSPIRE trial demonstrates that early administration of anakinra, guided by the presepsin biomarker, reduces the risk of organ dysfunction by 30% and significantly improves 90-day survival in hospitalized pneumonia patients, m
Browse by specialty
Open language-specific specialty feeds and department pages.